Jamie Dean

Dr. Jamie Dean

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Radiotherapy and Oncology
Verified
Journal Article
Open access
JDJamie Dean
Jamie Dean
KWKee H. Wong
Kee H. Wong
LWLiam C. Welsh
Liam C. Welsh
AJAnn-Britt Jones
Ann-Britt Jones
USUlrike Schick
Ulrike Schick
SGSarah L. Gulliford
Sarah L. Gulliford
Severe acute mucositis commonly results from head and neck (chemo)radiotherapy. A predictive model of mucositis could guide clinical decision-making and inform treatment planning. We aimed to generate such a model using spatial dose metrics and machine learning. Predictive models of severe acute mucositis were generated using radiotherapy dose (dose-volume and spatial dose metrics) and clinical data. Penalised logistic regression, support vector classification and random forest classification (RFC) models were generated and compared. Internal validation was performed (with 100-iteration cross-validation), using multiple metrics, including area under the receiver operating characteristic curve (AUC) and calibration slope, to assess performance. Associations between covariates and severe mucositis were explored using the models. The dose-volume-based models (standard) performed equally to those incorporating spatial information. Discrimination was similar between models, but the RFCstandard had the best calibration. The mean AUC and calibration slope for this model were 0.71 (s.d.=0.09) and 3.9 (s.d.=2.2), respectively. The volumes of oral cavity receiving intermediate and high doses were associated with severe mucositis. The RFCstandard model performance is modest-to-good, but should be improved, and requires external validation. Reducing the volumes of oral cavity receiving intermediate and high doses may reduce mucositis incidence.

10 August 2022 in Cell Genomics
Verified
Journal Article
Open access
HWHua-Jun Wu
Hua-Jun Wu
DTDaniel Temko
Daniel Temko
ZMZoltan Maliga
Zoltan Maliga
AMAndre L. Moreira
Andre L. Moreira
ESEmi Sei
Emi Sei
FMFranziska Michor
Franziska Michor
Intra-tumor heterogeneity (ITH) of human tumors is important for tumor progression, treatment response, and drug resistance. However, the spatial distribution of ITH remains incompletely understood. Here, we present spatial analysis of ITH in lung adenocarcinomas from 147 patients using multi-region mass spectrometry of >5,000 regions, single-cell copy number sequencing of ~2,000 single cells, and cyclic immunofluorescence of >10 million cells. We identified two distinct spatial patterns among tumors, termed clustered and random geographic diversification (GD). These patterns were observed in the same samples using both proteomic and genomic data. The random proteomic GD pattern, which is characterized by decreased cell adhesion and lower levels of tumor-interacting endothelial cells, was significantly associated with increased risk of recurrence or death in two independent patient cohorts. Our study presents comprehensive spatial mapping of ITH in lung adenocarcinoma and provides insights into the mechanisms and clinical consequences of GD.

1 December 2014 in Clinical Oncology
Verified
Journal Article
Closed access
LWLiam Welsh
Liam Welsh
ADA.W. Dunlop
A.W. Dunlop
TMT. McGovern
T. McGovern
DMD. McQuaid
D. McQuaid
JDJamie Dean
Jamie Dean
KNK.L. Newbold
K.L. Newbold

1 January 2020 in Radiotherapy and Oncology
Verified
Journal Article
Open access
JMJulia Murray
Julia Murray
CGClare Griffin
Clare Griffin
SGSarah Gulliford
Sarah Gulliford
ISIsabel Syndikus
Isabel Syndikus
JSJohn Staffurth
John Staffurth
DDDavid Dearnaley
David Dearnaley
Image-guided radiotherapy (IGRT) improves treatment set-up accuracy and provides the opportunity to reduce target volume margins. We introduced IGRT methods using standard (IGRT-S) or reduced (IGRT-R) margins in a randomised phase 2 substudy within CHHiP trial. We present a pre-planned analysis of the impact of IGRT on dosimetry and acute/late pelvic side effects using gastrointestinal and genitourinary clinician and patient-reported outcomes (PRO) and evaluate efficacy. CHHiP is a randomised phase 3, non-inferiority trial for men with localised prostate cancer. 3216 patients were randomly assigned to conventional (74 Gy in 2 Gy/fraction (f) daily) or moderate hypofractionation (60 or 57 Gy in 3 Gy/f daily) between October 2002 and June 2011. The IGRT substudy included a second randomisation assigning to no-IGRT, IGRT-S (standard CTV-PTV margins), or IGRT-R (reduced CTV-PTV margins). Primary substudy endpoint was late RTOG bowel and urinary toxicity at 2 years post-radiotherapy. Between June 2010 to July 2011, 293 men were recruited from 16 centres. Median follow-up is 56.9(IQR 54.3-60.9) months. Rectal and bladder dose-volume and surface percentages were significantly lower in IGRT-R compared to IGRT-S group; (p < 0.0001). Cumulative proportion with RTOG grade ≥ 2 toxicity reported to 2 years for bowel was 8.3(95% CI 3.2-20.7)%, 8.3(4.7-14.6)% and 5.8(2.6-12.4)% and for urinary 8.4(3.2-20.8)%, 4.6(2.1-9.9)% and 3.9(1.5-9.9)% in no IGRT, IGRT-S and IGRT-R groups respectively. In an exploratory analysis, treatment efficacy appeared similar in all three groups. Introduction of IGRT was feasible in a national randomised trial and IGRT-R produced dosimetric benefits. Overall side effect profiles were acceptable in all groups but lowest with IGRT and reduced margins. 97182923.

1 January 2018 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
JDJamie Dean
Jamie Dean
KWKee Wong
Kee Wong
HGHiram Gay
Hiram Gay
LWLiam Welsh
Liam Welsh
AJAnn-Britt Jones
Ann-Britt Jones
SGSarah Gulliford
Sarah Gulliford
• Machine learning-based NTCP modelling of acute dysphagia was performed. • The models generated performed well on internal and external validation. • Doses of approximately 1 Gy/fraction were most strongly associated with severe dysphagia. • No spatial variation in radiosensitivity was observed for the pharyngeal mucosa. • These results could inform clinical decision-support and radiotherapy planning.

16 April 2021 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
ARAmanda Randles
Amanda Randles
HWHans-Georg Wirsching
Hans-Georg Wirsching
JDJamie Dean
Jamie Dean
YCYu-Kang Cheng
Yu-Kang Cheng
SESamuel Jay Emerson
Samuel Jay Emerson
FMFranziska Michor
Franziska Michor
Glioblastoma stem-like cells dynamically transition between a chemoradiation-resistant state and a chemoradiation-sensitive state. However, physical barriers in the tumour microenvironment restrict the delivery of chemotherapy to tumour compartments that are distant from blood vessels. Here, we show that a massively parallel computational model of the spatiotemporal dynamics of the perivascular niche that incorporates glioblastoma stem-like cells and differentiated tumour cells as well as relevant tissue-level phenomena can be used to optimize the administration schedules of concurrent radiation and temozolomide—the standard-of-care treatment for glioblastoma. In mice with platelet-derived growth factor (PDGF)-driven glioblastoma, the model-optimized treatment schedule increased the survival of the animals. For standard radiation fractionation in patients, the model predicts that chemotherapy may be optimally administered about one hour before radiation treatment. Computational models of the spatiotemporal dynamics of the tumour microenvironment could be used to predict tumour responses to a broader range of treatments and to optimize treatment regimens.